PEVIA Consortium Submits 1st Intermediate Report
Founded in 2009, Vaxeal, in partnership with leading international research institutes, has developed fixed combinations of immunotherapy-based cancer treatments that overcome the immuno-suppressive environment surrounding cancer cells and target the specific tumors.
Recent scientific research has produced an exciting opportunity to develop advanced immunotherapies to treat cancers. Consistent human data has shown that cancer immunotherapies are overcoming both efficacy issues, by targeting specific cancer biomarkers, and safety issues, by limiting toxicity and immune-related adverse events induced by immune checkpoint blockades and standard of care therapies.
The central aim of all cancer immunotherapies is the induction of effective anti-tumor immunity in cancer patients leading to the elimination of tumors and long-lasting protection against relapses. Vaxeal is developing game-changing immunotherapies that meet the growing need for these improved treatments. Over 20 million new cases of cancer are predicted by 2025, compared with the recorded 12 million in 2008.
With this scenario, global sales of cancer drugs will grow significantly, surpassing US$100 billion by 2020. Immunotherapies are expected to lead this market growth.
Vaxeal is the convergence point for a diverse advanced expertise in tumor immunology and vaccine formulation, including predictive T-cell assays, ex-vivo assessment of T-cell responses in cancer patients, new relevant pre-clinical animal models, as well as optimal vaccine formulation.
Proprietary long synthetic peptide SVX-1 and CBX-1 vaccines, targeting broadly expressed tumour antigens, Survivin and Cyclin B-1, have been assessed for their immunogenicity in relevant preclinical models.
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.
Vaxeal target selection was based on expression and tumour cell vital functions. Survivin and Cyclin B1 are undetectable or transiently expressed in most normal adult tissues.
They are both over-expressed in most human cancers, and play vital functions in tumor cells. Both targets are associated with a poor prognosis.
Long peptides are vaccines able to generate strong and sustainable specific CD4+ and CD8+ T-cell responses in humans, irrespective of individual Human Leukocyte Antigen (HLA) types. In addition, Long Synthetic Peptides (LSPs) have the strong advantage to be safe and easy to manufacture compared to “biological vaccines” created from living organisms.
The efficacy of the cancer immunotherapies is further increased by their formulation with new adjuvants, and fixed combination with antibodies that modulate tumour-induced immune suppression (Immune Checkpoint Blockades).
Our state-of-the-art combined strategies overcome the limitations of traditional vaccine therapies.
Vaxeal is targeting disease segments where high value markets are experiencing rapid growth.
Vaxeal is conducting extensive pre-clinical studies with human cells, from healthy donors and cancer patients.
We overcome the limitations of current cancer vaccine development through innovative combined therapies.
ICBs overcome tumor-mediated immunosuppressive mechanisms: Modulate proliferation and suppressive functions of immunosuppressive cells (Regulatory CD4+ T-cells (Treg), Myeloid-derived suppressor cells or MDSCs).
ICBs boost vaccine-induced anti-tumoral immune responses: Improve proliferation, functions and therapeutic efficacy of the anti-tumor T-cell responses induced with the cancer vaccine.
Fixed combination of therapeutic vaccines with ICBs have the potential to reduce immune-related adverse events of ICBs: Reduction of ICB doses and treatment cycles.
Fixed combination of therapeutic vaccines with ICBs have the potential to increase clinical efficacy of cancer: Induction of specific and long-lasting anti-tumoral CD4+ and CD8+ T-cell responses; Block immune checkpoint pathways suppressing the anti-tumoral immune response in the tumor microenvironment.